ARS-1630 is primarily used in research and development within the pharmaceutical industry, particularly in the field of oncology. It is investigated for its potential as a therapeutic agent targeting specific pathways involved in cancer progression. Researchers focus on its ability to inhibit certain enzymes or proteins that play a critical role in tumor growth and metastasis. Its application is mostly confined to preclinical studies, where it is tested in vitro and in vivo to evaluate its efficacy, safety, and mechanism of action. The compound is also utilized in biomarker studies to understand its impact on cellular processes and its potential for combination therapies with other anticancer drugs.